[Progress in diagnosis and treatment of gastroparesis after colon cancer surgery]

At present, comprehensive treatment dominated by surgical procedures is an important measure for colon cancer to obtain the chance of cure. Surgical intervention, while removing the tumor, carries the risk of postoperative gastroparesis (PG) . Because of the low incidence rate and insignificant early clinical symptoms, early stage PG is often overlooked clinically. However, PG can increase the risk of malnutrition, delay postoperative antitumor treatment, and increase the risk of tumor recurrence and metastasis. This review focuses on the mechanisms, clinical risk factors, preventive measures, and advances in treatment of PG due to colon cancer. Aim to increase the clinician's adequate attention to PG in colon cancer and from a surgical point to reduce the risk of gastroparesis in colon cancer by optimizing the surgical strategy.

Risk factors for gastric paralysis in patients with severe acute pancreatitis

AIM

To identify the risk factors for gastric paralysis (GS) in patients with severe acute pancreatitis (SAP), in order to improve its diagnosis and therapy.

METHODS

Clinical data for 447 SAP patients treated from January 2011 to January 2016 at Department of General Surgery, Gansu Provincial Hospital were retrospectively analyzed. Risk factors for GS in SAP patients were identified by non-conditional Logistic regression analysis.

RESULTS

Univariate analysis showed that age, sex, body mass index (BMI), protein level, early enteral nutrition (EEN), early effective Chinese medicine, blood glucose level, scores of anxiety and depression were risk factors for GS in SAP patients. The non-conditional Logistic regression analysis showed that female sex, anxiety and depression were independent risk factors, while EEN, early effective Chinese medicine and high protein level were protective factors for GS in SAP patients.

CONCLUSION

Female sex, anxiety and depression are risk factors for GS in SAP patients. Earlier management of high-risk factors can help to prevent the occurrence of GS in SAP patients.

Roles of gastrin and somatostatin in ovarian cancer with gastroparesis syndrome

AIM: To determine roles of gastrin(GAS) and somatostatin(SS) in ovarian cancer with gastroparesis syndrome, and therefore to explore approaches to early diagnosis and treatment for ovarian cancer.

METHODS: Fifty-six patients with pathologically-confirmed ovarian cancer admitted to our hospital form January 2005 to January 2007 were divided into three groups: normal control group, ovarian benign tumor group and ovarian malignant tumor group. Radioimmunity method and RT-PCR were performed to measure expressions of GAS and SS in the serum and tissues. Their correlation with ovarian cancer were analyzed using t test.

RESULTS: In ovarian malignant tumor group, expression of serum GAS was elevated while serum SS was decreased. There was very significant difference between the malignant group and the control group (GAS: 146.6 ± 28.8 ng/L vs 83.5 ± 14.4 ng/L, SS: 16.2 ± 3.9 ng/L vs 52.1 ± 15.1 ng/L, both P < 0.01). There was significant difference between the malignant and benign tumor groups (GAS: 102.2 ± 21.5 ng/L, SS: 42.6 ± 13.6 ng/L, P < 0.05). There was significant difference between ovarian benign tumor group and normal control group (P < 0.05).

CONCLUSION: The expression level of GAS is increased, and SS is decreased in ovarian malignant tumor group. Celiac factors and body fluid factors may be responsible for these changes. This is helpful for the early diagnosis and treatments for ovarian cancer.